BGI-Shenzhen nailed down U.S. government approval for its controversial buyout of Complete Genomics, which would expand the Chinese sequencing powerhouse's technological capabilities in the competitive business of decoding DNA for medicine and agriculture.
Many groups rushed into the next-generation sequencing game over the past decade, so it's unsurprising to see news about some thinning of the genomics herd. Halcyon Molecular has shut down after other groups leapt ahead in bringing to market new technologies for decoding DNA quickly and inexpensively, GigaOm reported, citing unnamed sources.
Swiss drug giant Roche ($RHHBY) has erased DNA decoding outfit Illumina ($ILMN) from its M&A wish list, with the drugmaker preferring now to navigate the fast-changing DNA sequencing field via internal projects and partnerships. And Roche CEO Severin Schwan isn't fretting the failed buyout bid.
OpGen has struck a deal with investors to haul in as much as $17 million in a Series C round of financing, providing the company with growth capital to bolster sales of its genomic research tools and analysis software products.
Roche's $5.7 billion hostile bid to scoop up DNA sequencing machine maker Illumina ( $ILMN ) has triggered talk of further merger targets in the promising genomics arena.
As pharma companies expand their use of DNA sequencing for drug R&D, researchers have uncovered some potential new targets for existing cancer drugs that are likely to spur further use of
Other major pharma chiefs don't see the same opportunity in acquiring Illumina ( $ILMN ) as does Roche CEO Severin Schwan , whose company's $5.7 billion hostile takeover bid for the maker of DNA
A day after Roche's ( $RHHBY ) hostile $5.7 billion bid to scoop up Illumina ( $ILMN ) hit the news, investors are wagering that the maker of DNA sequencing machines will attract a better offer.
Amid efforts to gain control of an overwhelming surge in life sciences data, the U.K. government is spending £75 million on what is being called a "nerve centre" of a Europe-wide effort to
With third-quarter sales falling shy of Wall Street's expectations and looming budget cuts at the NIH feeding fears that researchers will have less money to spend on new DNA sequencing tech, Illumina